Takeda Makes Financial Moves To Trim Cash Flow While Adding R&D
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical is suspending its three-year practice of buying back its own stock as it tightens its belt to increase research-and-development spending at the same time it continues to pay dividends. The 6 percent R&D budget increase is considered by Takeda as critical to plans to develop badly needed new drugs to replace expiring patents. Takeda has cut expenses elsewhere and plans not to increase its dividend to stockholders this fiscal year. The halt in stock buybacks also is intended to maintain its cash reserve. (Click here for more - a subscription may be required